



Chemical shift assignments of the partially deuterated Fyn SH2–SH3 domain

Fabien Kieken^{1,2,3} · Karine Loth^{4,5} · Nico van Nuland^{1,2} · Peter Tompa^{1,2} · Tom Lenaerts^{3,6,7}

Received: 3 July 2017 / Accepted: 28 November 2017
© Springer Science+Business Media B.V., part of Springer Nature 2017

Abstract

Src Homology 2 and 3 (SH2 and SH3) are two key protein interaction modules involved in regulating the activity of many proteins such as tyrosine kinases and phosphatases by respective recognition of phosphotyrosine and proline-rich regions. In the Src family kinases, the inactive state of the protein is the direct result of the interaction of the SH2 and the SH3 domain with intra-molecular regions, leading to a closed structure incompetent with substrate modification. Here, we report the ¹H, ¹⁵N and ¹³C backbone- and side-chain chemical shift assignments of the partially deuterated Fyn SH3–SH2 domain and structural differences between tandem and single domains. The BMRB accession number is 27165.

Keywords SH3–SH2 · Tandem domains · NMR · Fyn kinase · Src family

Biological context

The Src family consists of 11 non-receptor tyrosine kinases involved in a plethora of fundamental biological processes including cell growth, differentiation, cellular adhesion, cell migration (Manning et al. 2002). The structural organization of each family member is equivalent: They are composed of

four different domains—SH1 to SH4—with a C-terminal negative regulatory tail. The SH4 domain located in the N-terminus anchors the proteins to the plasma membrane and is attributed with the varying physiological functions of the family members (Sato et al. 2009). SH3 and SH2 domains are involved in regulating kinase activity and mediate the interaction of the kinase with its protein partners, and SH1 is the kinase domain (Boggon and Eck 2004; Sicheri and Kuriyan 1997). Src family kinases (SFK) catalytic activity is determined by intermolecular interactions and equilibrium of phosphorylation-dephosphorylation states. Activation of the kinase is triggered by the dephosphorylation of the phospho-tyrosine in the C-terminus, which in turn results in the initiation of signaling cascades that drive basic cellular function (Huculeci et al. 2016; Xu et al. 1999). Given their important role in fundamental physiological and pathological processes, members of the SFK have been widely investigated in various biological contexts.

Fyn, one of the SFK members, regulates numerous cellular processes including motility, growth, differentiation and signal transduction in various cell types (Saito et al. 2010). The Fyn gene has three splice variants, one of which is deemed inactive. FynT is highly expressed in cells of hematopoietic lineage and regulates immune cell functions and inflammatory responses. The other active form FynB is ubiquitous, with the highest expression in the synaptic architecture of the central nervous system, playing important roles in glutamate receptor trafficking and synaptic

✉ Tom Lenaerts
Tom.Lenaerts@ulb.ac.be

¹ Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussel, Belgium

² Center for Structural Biology, VIB, Pleinlaan 2, 1050 Brussel, Belgium

³ AI-lab, Vakgroep Computerwetenschappen, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium

⁴ Centre de Biophysique Moléculaire, Centre National de la Recherche Scientifique (CNRS) UPR 4301, Université d'Orléans, rue Charles Sadron, 45071 Orléans Cedex 2, France

⁵ Collegium Sciences et Techniques, Université d'Orléans, rue de Chartres, 45100 Orléans, France

⁶ MLG, Département d'Informatique, Université Libre de Bruxelles, Boulevard du Triomphe, CP 212, 1050 Brussels, Belgium

⁷ Interuniversity Institute of Bioinformatics Brussels (IB2), ULB-VUB, La Plaine Campus, Boulevard du Triomphe, CP 263, 1050 Brussels, Belgium

49 plasticity (Grant et al. 1992; Kojima et al. 1998; Nakazawa
50 et al. 2001; Prybylowski et al. 2005; Suzuki and Okumura-
51 Noji 1995). Beyond its basic physiological functions, Fyn
52 has been widely investigated as a therapeutic target due to
53 its implication in the pathophysiology of various cancers,
54 neurodegenerative and psychiatric diseases (Nygaard et al.
55 2014; Ohnuma et al. 2003; Panicker et al. 2015). Fyn has
56 been found significantly upregulated in cancer tissues, with
57 its level correlating with aggressive disease progression and
58 metastasis [review (Elias and Ditzel 2015)], which results
59 from promoting cancer cell proliferation and inhibition of
60 cell death (Elias et al. 2015; Li et al. 2003). Inhibition of Fyn
61 function is thought to have therapeutic potential in cancer
62 and neurodegenerative conditions. Various inhibitors of Fyn
63 kinase domain are available; however these carry various
64 safety liabilities and long term toxicity due to lack of speci-
65 ficity in inhibiting kinase functions (Grant 2009).

66 Fyn's SH1 activity is regulated by the intramolecular
67 interactions with two of its domains, SH3 and SH2. SH3
68 domains interact primarily with sequences rich in proline,
69 such as PxxP motifs, although they can also bind other
70 sequences that deviate from the canonical one [review (Sak-
71 sela and Permi 2012)], whereas SH2 domains recognize and
72 bind phosphotyrosine residues (Pawson 1995). Fyn SH2 is
73 responsible for the state of activation of the kinase. Phos-
74 phorylated Tyr527 allows a direct interaction between Fyn
75 SH2 with the C-terminus, resulting in an inactive kinase
76 state. The kinase self-activation occurs during the dephos-
77 phosphorylation of Tyr527 and/or the binding of protein partners,
78 allowing the dissociation between SH3, SH2, and the kinase
79 domain [review in (Roskoski 2015)].

80 The mechanism of propagation of the information or
81 cross-communication between the two domains is not well
82 investigated and has led to controversial reports. While the
83 SH3 domain enhances Fyn SH2-mediated ligand binding
84 (Panchamoorthy et al. 1994) and the replacement of the
85 SH3–SH2 linker residues with glycines activates c-Src
86 (Young et al. 2001), the analysis of the dynamics of Fyn
87 SH3–SH2 by nuclear magnetic resonance (NMR) T_1/T_2 /
88 NOE, domain alignment by residual dipolar couplings
89 and crystallographic structure showed very little structural
90 modifications (Ulmer et al. 2002). Nonetheless, recent work
91 showed that sidechain dynamics plays a role in the activation
92 process (Huculeci et al. 2016).

93 As no solution structure by NMR of human wild type Fyn
94 SH3–SH2 is available, we report here on the full backbone
95 and side-chain ^1H , ^{15}N and ^{13}C assignment of partially deu-
96 terated ^{13}C , ^{15}N -labeled Fyn SH3–SH2 in its free form using
97 high-resolution NMR techniques. The anticipated structural
98 resolution of the tandem domains by NMR will provide
99 additional information on changes of structure and dynam-
100 ics between domains, hopefully providing an explanation

for the mechanism of information propagation throughout
the structure.

103 Methods and experiments

104 Protein expression and purification

105 The human Fyn SH3–SH2 domain (residues 82–248), SH3
106 domain (82–147) and SH2 domain (148–248) were sub-
107 cloned into a pet15b (Novagen) vector containing a throm-
108 bin-cleavable N-terminal hexa-His tag by standard cloning
109 methods.

110 Transformed BL21(DE3)star cells (Invitrogen) were
111 grown at 37 °C in 1 L of minimal medium implemented with
112 0.75 g $^{15}\text{NH}_4\text{Cl}$ and 2 g ^{13}C -glucose (Cambridge Isotope
113 Laboratories). The bacteria were induced at a cell density of
114 0.6 by addition of 0.5 mM IPTG and were then incubated at
115 22 °C overnight. The cells were pelleted by centrifugation at
116 7000×g and the pellet kept and stored at –80 °C for further
117 processing. The expression of the partially deuterated and
118 uniformly $^{13}\text{C}/^{15}\text{N}$ -labeled protein was achieved by making
119 the minimal medium 60% in D_2O (Cortecnet) complemented
120 with 0.75 g $^{15}\text{NH}_4\text{Cl}$ and 2 g ^{13}C -glucose.

121 The pellets were thawed and resuspended in lysis buffer
122 (20 mM Hepes pH 7.6, 100 mM Na_2SO_4 , 20 mM imidazole,
123 10 mM β -mercaptoethanol (BME), 10% glycerol containing
124 0.2 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride
125 (AEBSF), 5 $\mu\text{g}/\text{mL}$ leupeptin and 4 units/mL of DNase
126 I). The cells were lysed by sonication using a Sonics Vibra-
127 CellTM CV18 model ultrasonic processor (70% amplitude,
128 3 s pulse on/off for 10 min) and the lysates were centrifuged
129 at 20,000×g for 1 h at room temperature. The supernatant was
130 then loaded into a prepacked HisTrap column (GE Health-
131 care). The resin was washed with 10 column volume of lysis
132 buffer without protease inhibitor and DNase. The proteins
133 were eluted with 20 mM Hepes pH 7.6, 100 mM Na_2SO_4 ,
134 500 mM imidazole, 10 mM BME and 10% glycerol. The
135 eluted proteins were loaded into a gel filtration Econo-Pac
136 10DG column (Biorad) equilibrated with 20 mM Hepes
137 buffer pH 7.6, 100 mM Na_2SO_4 , 10 mM BME, 10% glycerol.
138 The protein were eluted using the same buffer and were con-
139 centrated by using 20 mL spinning Vivaspin 20 filters with a
140 10 kDa cut-off (Sartorius AG) to a concentration of 10 mg/mL.
141 The proteins were either snap frozen and stored at –80 °C or
142 incubated with 1 unit of thrombin (Calbiochem) per mg of
143 protein overnight at room temperature to remove the His-tag.
144 The cleaved Fyn SH3–SH2 was separated from the tag by
145 gel-filtration using a Superdex75 16/90 column (GE Health-
146 care) in 50 mM sodium phosphate buffer pH 6.5, 100 mM
147 Na_2SO_4 , 2 mM BME. The fractions containing the protein
148 were concentrated using a Vivaspin 20 filter with a 10 kDa

149 cut-off (Sartorius AG). SDS-PAGE was used to determine the
150 purity of the sample.

151 NMR spectroscopy

152 The concentration of partially deuterated $^{15}\text{N}/^{13}\text{C}$ sample of
153 Fyn SH3–SH2 used for assignment was 0.7 mM in 50 mM
154 sodium phosphate buffer pH 6.5, 100 mM Na_2SO_4 , 2 mM
155 BME, 10% D_2O . NMR data were acquired at 25 °C on a
156 Varian Direct-Drive System 600 MHz and an Avance III
157 HD Bruker 700 MHz spectrometers, both equipped with a
158 cryoprobe. Sequential assignments of the protein were car-
159 ried out using ^{15}N -HSQC, ^{13}C -HSQC, HNCOC, HNCA,
160 HNCACB, following classical procedures Side-chains
161 assignments were carried out using trosy-HBANH, trosy-
162 HBHA(CO)NH, HCCH-TOCSY, [^1H , ^{15}N]-HSQC NOESY
163 and [^1H , ^{13}C]-HSQC NOESY. Backbone assignments were
164 obtained using 2D ^{15}N -HSQC, ^{13}C -HSQC, 3D ^{15}N and ^{13}C
165 NOESY-HSQC (mixing time: 100 ms) and triple-resonance
166 experiments CBCACONH, HNCACB, HCCH-TOCSY,
167 HBANH, HBHACONH. 1D ^1H -detected ^{15}N -edited relaxa-
168 tion experiments were used to calculate the average ^{15}N T_1 and
169 T_2 relaxation by fitting the integrated signal in the backbone
170 amide ^1H region of the spectrum (10.5–8.5 ppm) as a function
171 of delay time to an exponential decay. ^{15}N T_1 and T_2 spec-
172 tra were acquired with a recycle delay of 8.0 s. T_1 relaxation
173 delays of 100, 200, 300, 400, 600, 800, 1000, 1500, 2000,
174 3000 and 5000 ms and T_2 relaxation delays of 10, 30, 50, 70,
175 90, 110, 130, 150, 170 ms were used for data collection. At
176 high magnetic field (above 500 MHz), the correlation time
177 of a molecule (τ_c) can be estimated for a rigid protein with
178 $\tau_c \gg 0.5$ ns as a function of the ratio of the longitudinal (T_1)
179 and transverse (T_2) ^{15}N relaxation times. By considering $J(0)$
180 and $J(\omega_N)$ spectral density terms and neglecting higher fre-
181 quency terms, the correlation time of a molecule can be esti-
182 mated using the following equation:

$$183 \tau_c \approx \frac{1}{4\pi\nu_N} \sqrt{6 \frac{T_1}{T_2} - 7},$$

184 where ν_N is the ^{15}N resonance frequency (in Hz) (Kay et al.
185 1989).

186 All 3D experiments were acquired using non-uniform
187 sampling. All NMR spectra were processed using NMRPipe
188 (Delaglio et al. 1995) or Bruker's Topspin 3.2TM and analysed
189 by NMRVIEW and CCPNMR (Johnson and Blevins 1994;
190 Vranken et al. 2005).

Assignment and data deposition

192 Analysis of Fyn SH3–SH2 domain 1D ^1H -detected
193 ^{15}N -edited relaxation experiments in solution showed
194 a direct relation between the protein correlation time
195 (τ_c) with its concentration, suggesting that the protein
196 under the conditions of the NMR experiments is a mono-
197 mer–dimer mixture (Fig. 1a) (Rossi et al. 2010). The cor-
198 relation time of a monomeric protein in solution in nano-
199 seconds is approximately 0.6 times its molecular weight in
200 kDa. For Fyn SH3–SH2, τ_c is estimated to be 11.8 ns. At
201 classical sample concentration for NMR structure deter-
202 mination (> 0.6 mM), the τ_c for Fyn SH3–SH2 is above
203 16.5 ns. The quality of HSQC spectra decreases with
204 incremental concentrations (Fig. 1b) and as a consequence,
205 use of uniformly-labeled $^{15}\text{N}/^{13}\text{C}$ sample yielded no signal
206 in all 3D experiments (Fig. 1c).

207 Nietlispach et al. showed that 50–60% random frac-
208 tional deuteration increases the sensitivity of the NMR
209 experiments due to the reduction of R_2 of the molecule,
210 allowing structure determination by NMR using ^{15}N and
211 ^{13}C NOESY-HSQC (Nietlispach et al. 1996). Using this
212 methodology on the Fyn SH3–SH2 domain, we observed a
213 significant improvement on the quality of the NMR spectra
214 (Fig. 1d). Using this approach with a 50% deuterated uni-
215 formly-labeled ^{15}N and ^{13}C Fyn SH3–SH2 resulted in 97%
216 of the backbone and 94% of all ^1H side chains assignment.
217 Due to the random nature of the deuteration processes, the
218 chemical shifts were not corrected for ^2H isotopes shifts.
219 The ^{15}N -HSQC spectrum and assignment are displayed in
220 Fig. 2a. The ^1H , ^{13}C and ^{15}N chemical shifts were depos-
221 ited into the BioMagResBank database ([http://www.brmb.
222 wisc.edu/](http://www.brmb.wisc.edu/)) accession number 27165.

223 To determine the percentage of monomer/dimer com-
224 plexes, we performed an analysis of 1D ^{15}N T_1/T_2 at
225 50–2000 μM concentrations (Fig. 1a). The estimated
226 K_D was calculated at 500 and 600 mM, suggesting that
227 more than 60% of Fyn SH2–SH3 exists as a dimer at
228 0.7 mM. For maintenance of dominant monomeric FYN—
229 SH3–SH2 in solution, lower concentrations (0.1–0.2 mM)
230 are necessary; however, such experimental prerequisites
231 hinder spectral assignment and structure determination
232 due to lack of signal.

233 Increasing sample concentrations above 1 mM also
234 resulted in loss of NMR signal (broadened peaks; Fig. 1b).
235 Dimer formation favoured by higher sample concentra-
236 tions exhibited as broadened peaks with the exception of
237 one peak (R96), which slightly shifted without creating
238 ambiguity for its assignment. Analysis of this chemical
239 shift perturbation enabled K_D determination in the range
240 of 500–700 mM. Thus a concentration of 0.7 mM was
241 subsequently selected for all the experiments in this study.




Fig. 1 Effect of protein concentration and deuteration on the NMR experiment and structural differences between Fyn SH3-SH2 and Fyn single domains SH2 and SH3. Plot of Fyn SH2-SH3 correlation time (τ_c) in function of protein concentration (**a**). Overlay of ^{15}N -HSQCs of the Fyn SH3-SH2 domain collected at different protein concentrations (**b**) (black: 50 μM ; gray: 100 μM ; light blue:

200 μM ; dark blue: 400 μM ; red: 600 μM ; green: 900 μM ; purple: 1.5 mM and dark green: 2 mM). 2D $^1\text{H}/^{13}\text{C}$ projection of the 3D HNCACB for a deuteration level of 0% (**c**) and 50% (**d**). ^{15}N -HSQC overlay spectra of Fyn SH3-SH2 domain (black) in the presence of the His tagged Fyn SH2 (**e**) and SH3 (**f**) domains (red). Residues affected by the presence of the tandem domains have been labeled

242 The chemical shift index (CSI) function and DANGLE
 243 (Cheung et al. 2010) modules in CCPNMR were used to
 244 predict the secondary structure of Fyn SH3-SH2 from
 245 backbone chemical shifts (Fig. 2b). The predicted second-
 246 ary structure is an arrangement of 6 β -strands for the SH3
 247 domain and 5 β -strands and 2 α -helices for SH2 domain,
 248 with a short α -helix in the linker between the two domains.
 249 These data further corroborate previous reports on the
 250 structure of SH2 and SH3, as a β -sandwich consisting of six
 251 strands flanked by 2 α -helices and connected by three loops
 252 and a β -sandwich consisting of five strands flanked by three
 253 loops and a short 3_{10} helix, respectively (Xu et al. 1999).

254 The structure of Fyn SH2 free in solution and in complex
 255 with the phosphorylated tail of the protein has been
 256 solved recently (Huculeci et al. 2016). We compared the

257 ^{15}N HSQC spectrum of the SH3-SH2 domain with the
 258 single SH2 domain under identical conditions to investi-
 259 gate if there is an effect of the SH3 domain on the struc-
 260 ture of SH2 domain. We observed the expected changes in
 261 the N-terminal region, but also throughout the sequence
 262 (Fig. 1e) suggesting a change in the structure of the
 263 SH2 domain when linked to the SH3 domain. A similar
 264 experiment using the free SH3 domain resulted in similar
 265 changes in the SH2 domain, with some still present, espe-
 266 cially in the loop area between b1 et b2 (Fig. 1f). These
 267 data underline the importance of studying these domains
 268 within the context of the tandem SH2-SH3 domain or even
 269 the full-length protein, as these differences may have an
 270 impact on the potential sidechain-induced communication
 271 between different parts of a protein.




Fig. 2 Assigned ^{15}N -HSQC spectrum and secondary structure prediction of the Fyn SH3–SH2 domain. **a** ^{15}N -HSQC spectrum of Fyn SH3–SH2 domain in 50 mM sodium phosphate buffer pH 6.5, 100 mM Na_2SO_4 , 2 mM BME, 10% D_2O . The assignments of backbone side chain amides and tryptophan indole groups are labeled.

b Threshold deviation from random coil ^{13}CO , $^{13}\text{C}\alpha$ and $^{13}\text{C}\beta$ were plotted as a function of residue number using the chemical shift index (CSI) module in CCPNMR. The cartoon represents the secondary structure of Fyn SH3–SH2 predicted by the CSI and DANGLE modules in CCPNMR

272 **Acknowledgements** This research is funded by the Flemish Scientific
273 Fund (F.W.O.) via the grant G025915N. The VIB and the Jean Jeener
274 NMR Center provided further support for our work.

275 References

276 Boggon TJ, Eck MJ (2004) Structure and regulation of Src family
277 kinases. *Oncogene* 23:7918–7927
278 Cheung MS, Maguire ML, Stevens TJ, Broadhurst RW (2010) DAN-
279 GLE: A Bayesian inferential method for predicting protein back-
280 bone dihedral angles and secondary structure. *J Magn Reson*
281 202:223
282 Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A (1995)
283 NMRPipe: a multidimensional spectral processing system based
284 on UNIX pipes. *J Biomol NMR* 6:277–293
285 Elias D, Ditzel HJ (2015) Fyn is an important molecule in cancer
286 pathogenesis and drug resistance. *Pharmacol Res* 100:250–254
287 Elias D, Vever H, Laenkholtm AV, Gjerstorff MF, Yde CW, Lykkesfeldt
288 AE, Ditzel HJ (2015) Gene expression profiling identifies FYN
289 as an important molecule in tamoxifen resistance and a predictor

of early recurrence in patients treated with endocrine therapy. 290
Oncogene 34:1919–1927 291
Grant SK (2009) Therapeutic protein kinase inhibitors. *Cell Mol Life* 292
Sci 66:1163–1177 293
Grant SG, O’Dell TJ, Karl KA, Stein PL, Soriano P, Kandel ER (1992)
294 Impaired long-term potentiation, spatial learning, and hippocam-
295 pal development in fyn mutant mice. *Science* 258:1903–1910 296
Huculeci R et al (2016) Dynamically coupled residues within the
297 SH2 domain of Fyn are key to unlocking its activity. *Structure*
298 24:1947–1959 299
Johnson BA, Blevins RA (1994) NMR view: a computer program
300 for the visualization and analysis of NMR data. *J Biomol NMR*
301 4:603–614 302
Kay LE, Torchia DA, Bax A (1989) Backbone dynamics of proteins
303 as studied by ^{15}N inverse detected heteronuclear NMR spec-
304 troscopy: application to staphylococcal nuclease. *Biochemistry*
305 28:8972–8979 306
Kojima N, Ishibashi H, Obata K, Kandel ER (1998) Higher seizure sus-
307 ceptibility and enhanced tyrosine phosphorylation of *N*-methyl-
308 *D*-aspartate receptor subunit 2B in fyn transgenic mice. *Learn*
309 *Mem* 5:429–445 310
Li X et al (2003) Alphavbeta6-Fyn signaling promotes oral cancer
311 progression. *J Biol Chem* 278:41646–41653 312

- 313 Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002)
314 The protein kinase complement of the human genome. *Science*
315 298:1912–1934
- 316 Nakazawa T et al (2001) Characterization of Fyn-mediated tyrosine
317 phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the
318 N-methyl-D-aspartate receptor. *J Biol Chem* 276:693–699
- 319 Nietlisbach D et al (1996) An approach to the structure determina-
320 tion of larger proteins using triple resonance nmr experiments in
321 conjunction with random fractional deuteration. *J Am Chem Soc*
322 118:407–415
- 323 Nygaard HB, van Dyck CH, Strittmatter SM (2014) Fyn kinase inhibi-
324 tion as a novel therapy for Alzheimer's disease. *Alzheimers Res*
325 Ther 6:8
- 326 Ohnuma T, Kato H, Arai H, McKenna PJ, Emson PC (2003) Expres-
327 sion of Fyn, a non-receptor tyrosine kinase in prefrontal cortex
328 from patients with schizophrenia and its correlation with clinical
329 onset. *Brain Res Mol Brain Res* 112:90–94
- 330 Panchamoorthy G et al (1994) Physical and functional interactions
331 between SH2 and SH3 domains of the Src family protein tyrosine
332 kinase p59fyn. *Mol Cell Biol* 14:6372–6385
- 333 Panicker N et al (2015) Fyn kinase regulates microglial neuroinflam-
334 matory responses in cell culture and animal models of parkinson's
335 disease. *J Neurosci* 35:10058–10077
- 336 Pawson T (1995) Protein modules and signalling networks. *Nature*
337 373:573–580
- 338 Prybylowski K, Chang K, Sans N, Kan L, Vicini S, Wenthold RJ (2005)
339 The synaptic localization of NR2B-containing NMDA receptors
340 is controlled by interactions with PDZ proteins and AP-2. *Neuron*
341 47:845–857
- Roskoski R Jr (2015) Src protein-tyrosine kinase structure, mechanism,
and small molecule inhibitors. *Pharmacol Res* 94:9–25
- Rossi P et al (2010) A microscale protein NMR sample screening pipe-
line. *J Biomol NMR* 46:11–22
- Saito YD, Jensen AR, Salgia R, Posadas EM (2010) Fyn: a novel
molecular target in cancer. *Cancer* 116:1629–1637
- Saksela K, Permi P (2012) SH3 domain ligand binding: What's the
consensus and where's the specificity? *FEBS Lett* 586:2609–2614
- Sato I et al (2009) Differential trafficking of Src, Lyn, Yes and Fyn is
specified by the state of palmitoylation in the SH4 domain. *J Cell*
Sci 122:965–975
- Sicheri F, Kuriyan J (1997) Structures of Src-family tyrosine kinases.
Curr Opin Struct Biol 7:777–785
- Suzuki T, Okumura-Noji K (1995) NMDA receptor subunits epsilon
1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the
postsynaptic density fraction isolated from the rat brain. *Biochem*
Biophys Res Commun 216:582–588
- Ulmer TS, Werner JM, Campbell ID (2002) SH3-SH2 domain orienta-
tion in Src kinases: NMR studies of Fyn. *Structure* 10:901–911
- Vranken WF et al (2005) The CCPN data model for NMR spectroscopy:
development of a software pipeline. *Proteins* 59:687–696
- Xu W, Doshi A, Lei M, Eck MJ, Harrison SC (1999) Crystal structures
of c-Src reveal features of its autoinhibitory mechanism. *Mol Cell*
3:629–638
- Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J (2001)
Dynamic coupling between the SH2 and SH3 domains of c-Src
and Hck underlies their inactivation by C-terminal tyrosine phos-
phorylation. *Cell* 105:115–126